Virobay, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.virobayinc.com
Clinical Trials
4
Active:0
Completed:4
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Virobay Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT01947738
- Locations
- 🇺🇸
Covance Evansville, Evansville, Indiana, United States
Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Virobay Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01911637
- Locations
- 🇺🇸
Covance Evansville, Evansville, Indiana, United States
Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Virobay Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01892891
- Locations
- 🇺🇸
Covance Evansville, Evansville, Indiana, United States
Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults
Phase 1
Completed
- Conditions
- Chronic Hepatitis C Infection
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Virobay Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00557583
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
News
No news found